Last reviewed · How we verify
ADX-2191
ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation.
ADX-2191 is designed to inhibit the activity of Rho-associated protein kinase (ROCK), which is involved in various cellular processes including inflammation and cell proliferation. Used for Proliferative vitreoretinopathy (PVR).
At a glance
| Generic name | ADX-2191 |
|---|---|
| Sponsor | Aldeyra Therapeutics, Inc. |
| Drug class | ROCK inhibitor |
| Target | ROCK |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting ROCK, ADX-2191 aims to reduce inflammation and prevent abnormal cell growth, which can be beneficial in treating certain ocular conditions such as proliferative vitreoretinopathy (PVR).
Approved indications
- Proliferative vitreoretinopathy (PVR)
Common side effects
- Eye pain
- Increased intraocular pressure
Key clinical trials
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma (PHASE3)
- The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy (PHASE3)
- A Study in Subjects With Retinitis Pigmentosa (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |